ElevateBio
Powering the creation of cell & gene therapies at a speed the world deserves.
by
Larry has more than 20 years of leadership experience and deep technical expertise, with proven success in building and scaling commercial teams, driving revenue growth, and establishing global partnerships. Currently, Larry is the Chief Commercial Officer at ElevateBio where he leads commercial strategy to accelerate revenue growth by expanding partnerships across ElevateBio’s BaseCamp manufacturing and Life Edit gene editing businesses.
by
Aaron Nudelman joined ElevateBio in 2020, and as SVP, Head of Intellectual Property, he leads the Company’s IP function overseeing patent preparation, prosecution, maintenance, and enforcement; IP diligence and strategy; and IP aspects of license negotiation and related transactions.
by
Michael has spent the last twenty years in biotechnology building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late-stage clinical trials. Currently, Michael is the Chief Technology Officer at ElevateBio BaseCamp and is responsible for BaseCamp’s technology offerings, including cell therapy, LentiPeakTM platform, and process development.
by
Bryan Rizzo joined ElevateBio in 2025 and as Senior Vice President, Head of Quality, he is responsible for overseeing the harmonization of quality operations across multiple cell and gene therapy research and manufacturing locations. He ensures regulatory compliance and risk-based decision-making within scalable and sustainable processes across the organization.
by
Amy leads research and development at Life Edit Therapeutics. She has more than 20 years of scientific leadership and expertise with an extensive background in genetic medicine, neuroscience, drug development, and scientific strategy.
by
Katie Jorgensen joined ElevateBio in 2021 and as Site Head at BaseCamp, she is responsible for supply chain, facilities, technical operations, manufacturing, and program management supporting strategic contracts and valued partnerships bringing innovative cell and gene therapies to patients. Previously, she was the Company’s VP, Commercial Operations and CMC Program Management.
by
Tess Kitchener has twenty years of experience in biotech, with the majority in CMC leadership roles, including those in process development, manufacturing technical support, and manufacturing. Currently, Tess is leading the BaseCamp Commercial team and is responsible for Business Development, Marketing and Commercial Operations for BaseCamp.
by
Sean has over 25 years of experience in Quality Assurance, Quality Control, Compliance, CMC Regulatory Affairs, Process Development, Validation, and Manufacturing Sciences. He has deep expertise in quality systems and product lifecycle management across all phases of drug development and commercial supply. Currently, Sean is the Vice President, Quality Site Head at ElevateBio BaseCamp and is responsible for leading site quality operations, ensuring regulatory compliance, and supporting commercial manufacturing readiness.
by
Katherine has over 20 years of experience in biomanufacturing operations including multiple new facility startups. She currently serves as Site Head, BaseCamp Pittsburgh and is responsible for supply chain, facilities, technical operations, manufacturing, and program management.
by
Ron leads technology development in gene editing at Life Edit Therapeutics. He has more than 25 years of experience in the biotech industry, focusing on developing and applying innovative protein platforms for enzyme and protein therapeutic applications.
by
As Senior Director, Translational Biology at Life Edit Therapeutics, Michael specializes in using protein engineering and bioconjugation to create novel therapeutics and utilizes his interdisciplinary background to evaluate and optimize them.
by
April provides operational support for manufacturing of gene editing drug products for clinical and commercial application of Life Edit Therapeutics and its partners’ portfolio of therapeutics, facilitating the seamless transfer of technology through process and analytical development, material for toxicology studies and GMP manufacture. She has more than 10 years of pharmaceutical industry experience, preceded by many years in academic research.
